PRENETICS GLOBAL LTD-CL A (PRE) Stock Overview
USA - NASDAQ:PRE - KYG722451229 - Common Stock
PRE Key Statistics, Chart & Performance
The current stock price of PRE is 13.82 USD. In the past month the price decreased by -5.34%. In the past year, price increased by 199.13%.
PRE Latest News, Press Relases and Analysis
PRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.77 | 102.23B | ||
| CI | THE CIGNA GROUP | 10.65 | 79.84B | ||
| LH | LABCORP HOLDINGS INC | 15.69 | 20.62B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 208.89 | 20.35B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.91 | 19.54B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.32 | 15.79B | ||
| HIMS | HIMS & HERS HEALTH INC | 58.29 | 10.54B | ||
| DVA | DAVITA INC | 13.05 | 9.05B | ||
| GH | GUARDANT HEALTH INC | N/A | 9.01B | ||
| CHE | CHEMED CORP | 21.16 | 6.78B | ||
| RDNT | RADNET INC | 219 | 6.06B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 61.91 | 6.03B |
Related stock screener links
About PRE
Company Profile
Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The company employs 285 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
Company Info
PRENETICS GLOBAL LTD-CL A
Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
Hong Kong HM 08 HK
CEO: David Zwiener
Employees: 285
Phone: 85222109588
PRENETICS GLOBAL LTD-CL A / PRE FAQ
What does PRENETICS GLOBAL LTD-CL A do?
Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The company employs 285 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
Can you provide the latest stock price for PRENETICS GLOBAL LTD-CL A?
The current stock price of PRE is 13.82 USD. The price increased by 13% in the last trading session.
What is the dividend status of PRENETICS GLOBAL LTD-CL A?
PRE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRE stock?
PRE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of PRENETICS GLOBAL LTD-CL A (PRE)?
PRENETICS GLOBAL LTD-CL A (PRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.68).
Would investing in PRENETICS GLOBAL LTD-CL A be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRE.
Can you provide the growth outlook for PRENETICS GLOBAL LTD-CL A?
The Revenue of PRENETICS GLOBAL LTD-CL A (PRE) is expected to decline by -56.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
PRE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PRE. When comparing the yearly performance of all stocks, PRE is one of the better performing stocks in the market, outperforming 97.2% of all stocks.
PRE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRE. While PRE seems to be doing ok healthwise, there are quite some concerns on its profitability.
PRE Financial Highlights
Over the last trailing twelve months PRE reported a non-GAAP Earnings per Share(EPS) of -4.68. The EPS increased by 85.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.5% | ||
| ROE | -31.41% | ||
| Debt/Equity | 0 |
PRE Forecast & Estimates
5 analysts have analysed PRE and the average price target is 26.52 USD. This implies a price increase of 91.9% is expected in the next year compared to the current price of 13.82.
For the next year, analysts expect an EPS growth of 20.64% and a revenue growth -56.61% for PRE